IBX Secures Firm Commitments for $3.75m for Clinical Trial
Released
Released
Announcement PDF
Imagion Biosystems Limited
ASX: IBX
Imagion Biosystems Limited
ASX: IBX ACN 616 305 027
Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000
imagionbiosystems.com | investor@imagionbio.com
A S X A N N O U N C E M E N T | 2 5 J U N E 2 0 2 6
IBX Secures Firm Commitments for $3.75m To
Fund Clinical Trial Commencement
Imagion Biosystems (ASX: IBX) (Company or Imagion), a company dedicated to improving healthcare outcomes
through early and more accurate detection of cancers using its proprietary MagSense® molecular imaging
technology, is pleased to announce the Company has received $3.75 million of firm commitments under a strongly
supported capital raising.
This capital raising was led by CPS Capital Group Pty Ltd (CPS Capital), as a placement of ordinary shares to
Australian sophisticated investors and family offices raising $3.75m following the recently announced clearance by
the FDA of the Company’s Investigational New Drug (IND) application. The proceeds will be used to fund the
commencement of the MagSense® HER2 imaging agent Phase 1b/2 clinical trial across multiple sites in the USA.
IBX Executive Chairman, Robert Proulx commented, “We are very pleased with the strong demand we saw from
investors following our milestone achievement receiving clearance from the FDA for our MagSense® imaging to
proceed with the clinical trial. The successful submission of the IND represents a major technical and organisational
accomplishment for the company being recognised by our shareholders and the markets. With this kind of
shareholder support we can continue to advance our MagSense® molecular imaging technology and change how
cancer is detected. I want to thank CPS Capital for their lead role and all the investors who have shown their
support.”
Details of $3.75m Capital Raising
The Company will raise $3.75m of new capital (before costs) through a 2-tranche placement of new fully paid ordinary
shares (New Shares) to sophisticated professional investors, with each investor in the placement to receive one free
attaching IBXO listed option (Listed Options) for every two New Shares acquired (Placement). The Placement was
managed by CPS Capital (Broker and Lead Manager), with support from investors exceeding expectations.
The issue price for the Placement was $0.012 per New Share. The Listed Options will be issued under the same terms
as the Company’s existing listed options (IBXO), exercisable at $0.04 per listed option and expire on 13 December
2027. The offer price of the New Shares represents a 24.32% discount to the 10-day volume-weighted average price
(VWAP) before the date the capital raising was announced.
The Directors and management have agreed to subscribe for New Shares up to the value of $100,000 of as part of the
capital raising on the same terms and conditions, subject to shareholder approval at an Extraordinary General Meeting
(EGM), expected to be held in August 2026.
The Placement will comprise of two tranches:
Imagion Biosystems Limited
ASX: IBX
Imagion Biosystems Limited
ASX: IBX ACN 616 305 027
Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000
imagionbiosystems.com | investor@imagionbio.com
• Tranche 1: Placement of 49.3 million new shares at $0.012 per New Share to raise approximately $592,000
utilising the Company’s existing placement capacity under ASX Listing Rule 7.1, and
• Tranche 2: The issue of the balance of shares, representing a value of approximately $3.2 million, is
conditional upon the Company obtaining shareholder approval at an EGM.
A resolution to approve the issue of the free attaching New Listed Options attributable to both tranches will also be
put to shareholders at the EGM.
The Broker and Lead Manager is to receive a capital raising fee of 4% and a 2% management fee on the gross proceeds
received from the Placement. CPS Capital will also receive a tranche of 30,000,000 IBXO listed options (Lead Manager
Options). The Lead Manager Options are to be approved by shareholders at the EGM.
Use of Proceeds
Placement funds will be used primarily to fund the start of the Phase 1b/2 Clinical Trial in HER2+ Breast Cancer. The
Company has commenced trial activation activities for its HER2 Breast Cancer Phase 1b/2 clinical trial, and expects
patient recruitment to begin later in Q3 of this year. Key activities include:
• The initiation of the clinical trial and completion of the first cohort of patients;
• On-going drug manufacturing activities of the MagSense® imaging agent to support clinical development;
• Development of Intellectual Property (IP) related to molecular MRI; and
• Collaborations with leading MRI experts to further develop quantitative MRI techniques and AI-based
modelling optimised for the MagSense® imaging technology.
As previously disclosed, the trial consists of multiple parts as shown in the below scheme. The Company anticipates
progress over the near term to include, commencement of enrolment, first patient dosed, and completion of the first
cohort of participants.
Imagion Biosystems Limited
ASX: IBX
Imagion Biosystems Limited
ASX: IBX ACN 616 305 027
Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000
imagionbiosystems.com | investor@imagionbio.com
Indicative Timetable
The settlement of the Tranche 1 is expected to occur on Monday, 29 June 2026 and allotment and normal trading of
New Shares under Tranche 1 is expected to occur on Tuesday, 30 June 2026.
Trading halt lifted, and shares recommence
trading on ASX
Thursday, 25 June 2026
Settlement of Tranche 1 Monday, 29 June 2026
Allotment and normal trading of New Shares
under Tranche 1
Tuesday, 30 June 2026
General Meeting August 2026
Settlement, allotment and normal trading of New
Shares under Tranche 2 and New Listed Options under
Tranche 1 & 2
August 2026 – Soon after the approval of shareholder is
received at the General Meeting
The timetable is indicative only and remains subject to change at the Company’s discretion, subject to compliance
with applicable laws and the ASX Listing Rules. The Company reserves the right to change the timetable at any time
before New Shares and New Options are issued, subject to regulatory requirements.
All New Shares and New Listed Options issued under the Placement will rank equally with existing shares and listed
options on issue. An Appendix 3B for the proposed issue of securities will follow this announcement.
Authorisation & Additional Information
This announcement was authorised by the Board of Imagion Biosystems Limited.
-END-
About Imagion Biosystems
Imagion Biosystems (ASX: IBX) is a clinical-stage, medical imaging company dedicated to transforming how cancer is
diagnosed and treated. The company produced and is developing clinical applications for MagSense®, a first-of-its-
class MRI imaging agent that enables clinicians to detect cancer earlier and with greater precision. Advancing
molecular MRI, the company is using non-radioactive, bio-safe magnetic nanoparticles to improve diagnostic certainty
for a broad range of applications, including HER2+ breast cancer, prostate cancers, and ovarian cancers. For more
information, visit imagionbiosystems.com.
Executive Chairman Contact Details
Bob Proulx
investor@imagionbio.com
AU: +61 3 9692 7222
Media Enquiries & Investor Relations
Erich Boileau, Boileau & Co.
imagionbio@boileau.co
US : +1 (616) 786-4461
Share your feedback
Discover